0.21
+0.0029(+1.40%)
Currency In USD
Previous Close | 0.21 |
Open | 0.2 |
Day High | 0.21 |
Day Low | 0.2 |
52-Week High | 1.49 |
52-Week Low | 0.2 |
Volume | 3.52M |
Average Volume | 1.78M |
Market Cap | 18.54M |
PE | -0.21 |
EPS | -1 |
Moving Average 50 Days | 0.27 |
Moving Average 200 Days | 0.4 |
Change | 0 |
If you invested $1000 in Beyond Air, Inc. (XAIR) since IPO date, it would be worth $71.19 as of April 25, 2025 at a share price of $0.21. Whereas If you bought $1000 worth of Beyond Air, Inc. (XAIR) shares 5 years ago, it would be worth $27.74 as of April 25, 2025 at a share price of $0.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
GlobeNewswire Inc.
10 hours ago
GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
GlobeNewswire Inc.
Apr 21, 2025 8:05 PM GMT
The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON, April 21, 2
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
GlobeNewswire Inc.
Apr 15, 2025 8:05 PM GMT
Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s DiseaseBOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical com